- Home
- ETON vs TLSA Comparison
ETON vs TLSA Comparison
Compare ETON & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- TLSA
- Stock Information
- Founded
- ETON 2017
- TLSA 2013
- Country
- ETON United States
- TLSA United Kingdom
- Employees
- ETON N/A
- TLSA N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- TLSA Health Care
- Exchange
- ETON Nasdaq
- TLSA Nasdaq
- Market Cap
- ETON 199.5M
- TLSA 87.8M
- IPO Year
- ETON 2018
- TLSA 2000
- Fundamental
- Price
- ETON $8.82
- TLSA $1.20
- Analyst Decision
- ETON Strong Buy
- TLSA
- Analyst Count
- ETON 3
- TLSA 0
- Target Price
- ETON $12.00
- TLSA N/A
- AVG Volume (30 Days)
- ETON 214.1K
- TLSA 145.8K
- Earning Date
- ETON 11-11-2024
- TLSA 05-10-2024
- Dividend Yield
- ETON N/A
- TLSA N/A
- EPS Growth
- ETON N/A
- TLSA N/A
- EPS
- ETON N/A
- TLSA N/A
- Revenue
- ETON $31,381,000.00
- TLSA N/A
- Revenue This Year
- ETON $19.61
- TLSA N/A
- Revenue Next Year
- ETON $35.39
- TLSA N/A
- P/E Ratio
- ETON N/A
- TLSA N/A
- Revenue Growth
- ETON 8.14
- TLSA N/A
- 52 Week Low
- ETON $3.03
- TLSA $0.41
- 52 Week High
- ETON $8.66
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- TLSA 65.44
- Support Level
- ETON $7.58
- TLSA $0.83
- Resistance Level
- ETON $8.66
- TLSA $0.92
- Average True Range (ATR)
- ETON 0.42
- TLSA 0.09
- MACD
- ETON -0.07
- TLSA 0.03
- Stochastic Oscillator
- ETON 91.49
- TLSA 84.52
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.